SHR 9539
Alternative Names: SHR-9539Latest Information Update: 23 Aug 2024
At a glance
- Originator Suzhou Suncadia Biopharmaceuticals
- Class Antineoplastics
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 07 Aug 2024 Phase-I clinical trials in Multiple myeloma in China (Parenteral) (NCT06484777)
- 16 Jul 2024 Suzhou Suncadia Biopharmaceuticals plans a phase I trial for Multiple myeloma in China (Parenteral, Injection) (NCT06484777)
- 16 Jul 2024 Preclinical trials in Multiple myeloma in China (Parenteral, Injection) Prior to July 2024.